Pointe-Claire, Canada

Malay Doshi

USPTO Granted Patents = 1 

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Malay Doshi: Innovator in Cancer Treatment

Introduction

Malay Doshi is a prominent inventor based in Pointe-Claire, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating cancer. His innovative work has led to the creation of a patent that showcases his expertise and dedication to advancing medical science.

Latest Patents

Malay Doshi holds a patent for Pyrrolotriazine compounds and methods of inhibiting TAM kinases. This patent describes compounds, methods of making such compounds, pharmaceutical compositions, and medicaments that comprise these compounds. The methods outlined in the patent are designed to utilize these compounds in the treatment of cancer, highlighting the potential impact of his work on cancer therapies.

Career Highlights

Malay Doshi is currently employed at Syros Pharmaceuticals, Inc., where he continues to push the boundaries of pharmaceutical innovation. His role at the company allows him to collaborate with other talented professionals in the field, contributing to the development of groundbreaking treatments.

Collaborations

Some of his notable coworkers include David C. Moebius and Jason J. Marineau. Their collective expertise fosters an environment of innovation and collaboration, which is essential for advancing research and development in the pharmaceutical industry.

Conclusion

Malay Doshi's contributions to cancer treatment through his innovative patents and work at Syros Pharmaceuticals, Inc. exemplify the vital role of inventors in the medical field. His dedication to improving patient outcomes through scientific advancements is commendable and highlights the importance of continued research in cancer therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…